| Bili Wu,Bo Liu,Xueyan Jiang,Ye Yuan,Wan Qin,Kai Qin,Qi Mei,Li Zhang,Huilan Zhang,Guangyuan Hu,Xianglin Yuan. Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies. Oncol Transl Med, 2021, 7: 108-114. |
| Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies |
| Received:April 03, 2021 Revised:June 17, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:coronavirus disease (COVID-19); cancer; immunoglobulin (Ig) G; IgM |
| Author Name | Affiliation | E-mail | | Bili Wu | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | billywu2020@outlook.com | | Bo Liu | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Xueyan Jiang | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Ye Yuan | Department of Gastroenterology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Wan Qin | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Kai Qin | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Qi Mei | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Li Zhang | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Huilan Zhang | Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Guangyuan Hu | Department of Oncology, Tongji Hospital, Tongji Medical College, University of Science and Technology | | | Xianglin Yuan | Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China | yuanxianglin@hust.edu.cn |
|
| Hits: 3794 |
| Download times: 4382 |
| Abstract: |
| Objective: The aim of this study was to examine the seroprevalence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) among patients with cancer and followed up changes in SARS-CoV-2-specific
antibodies to explore the impact of anti-tumor treatment in patients.
Methods: Patients with cancer who visited the Outpatient Clinic of Oncology, Tongji Hospital, Tongji
Medical College, Huazhong University of Science and Technology, Wuhan, China between March 9 and
April 30, 2020 were enrolled in this retrospective cohort study. SARS-CoV-2 immunoglobulin (Ig) G, IgM,
and viral load at various time points during the disease course were determined.
Results: We examined the serological results of 779 patients with cancer. The overall seroprevalence
(IgG-positive or IgM-positive) rate of SARS-CoV-2 was 3.4%. The probability of seropositivity was
significantly higher in patients with gastric cancer than in those without gastric cancer (odds ratio: 6.349,
95% confidence interval: 2.191–18.396). Follow-up data showed that SARS-CoV-2 IgM and IgG levels
decreased and the polymerase chain reaction test result remained negative in seropositive patients with
cancer.
Conclusion: This study investigated the seroprevalence of SARS-CoV-2 in coronavirus disease (COVID-
19)-positive patients with cancer in Wuhan, China. The seropositivity in patients with cancer was lower than
or similar to that in the general population. Irrespective of anti-tumor therapy, the levels of SARS-CoV-2
antibodies decreased in these patients. More studies are needed to better understand the impact of antitumor
therapy on change in the levels of SARS-CoV-2 antibodies. |
| Close |
|
|
|